Search Results

responsiveness to the anti–epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab. 9 , 10 Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has also been shown to improve survival in the first

empiric, usually a platinum-based doublet. However in 2006, the FDA approved use of the anti-vascular endothelial growth factor monoclonal antibody, bevacizumab, with paclitaxel and carboplatin (PCB). This approval was based on the results of the ECOG

therapies, including immunotherapies (interleukin-2 and nivolumab) and molecularly targeted therapies, which comprise angiogenesis inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, and, with a characteristic target spectrum, the recently

a phase II randomized trial for patients with lung cancer. The study is titled TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing

antiangiogenic agent. In addition, agents with antiangiogenic properties have shown single-agent activity in this disease. Sorafenib has been shown to have a 14% response rate in angiosarcomas in previously treated patients in the phase II setting. Bevacizumab

and risks and discuss them thoroughly with their physician.” Dr. Morgan discussed 2 additional phase III trials assessing bevacizumab (Avastin, Genentech/Roche) combined with carboplatin/paclitaxel in the upfront setting compared with carboplatin

. In addition, agents with antiangiogenic properties have shown single-agent activity in this disease. Sorafenib has been shown to have a 14% response rate in patients with previously treated angiosarcomas in the phase II setting. Bevacizumab has

addition, agents with antiangiogenic properties have shown single-agent activity in this disease. Sorafenib has been shown to have a 14% response rate in angiosarcomas in previously treated patients in the phase II setting. Bevacizumab has demonstrated a 12

strategy remains controversial, and is typically reserved for patients with SSTa-resistant disease. 11 , 14 , 29 Notably, treatment with interferon is the control arm for an ongoing randomized phase III study exploring the use of bevacizumab in patients on

efficacy of chemotherapy + cetuximab (Cet) or panitumumab (Pani) versus chemotherapy ± bevacizumab (Bev) reported significant improvement in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with chemotherapy + Cet